Honor launched the Watch 6 Pro in China on September 28, and the headline feature is not a heart rate alert. It's a watch that decides your pulse has stopped, then goes looking for someone who can help you.
Honor calls it cardiac arrest monitoring. It's a four-level response system, and the escalation is the part worth understanding.
What the Watch Actually Does
The Watch 6 Pro runs its assessment in the background. Honor says the initial dynamic check takes about 1.5 to 3 seconds. If the suspected cardiac arrest condition persists past three seconds, the watch moves to a strong vibration warning.
At the highest risk level it does considerably more than buzz. According to Honor, the watch can:
- Call your emergency contacts
- Display AED resuscitation instructions across the screen
- Send a request for help to people nearby
- Use two-way satellite communication if the cellular network is down
That last one is the genuinely new piece. Existing cardiac arrest detection assumes the watch can reach the network. Honor is building for the case where it can't.
The company says it identifies a baseline using dual-wavelength sensing, cross-checks it with multiple wavelengths, runs a strong-light terminal probe, and factors in user behaviour recognition. The result is a four-tier risk classification rather than a single threshold crossing.
The Fine Print Is Substantial
This is where the feature stops being simple.
You have to join Honor's cardiac arrest warning research programme to use it. This is not an opt-in toggle buried in a settings menu for a shipping feature. It's a research programme.
Then there's the setup. For the escalation to work at all, you need emergency contacts configured in the Honor Health app, SMS permission granted, and the Bluetooth link to your phone kept alive. The watch cannot call anyone on its own without that chain intact.
Honor also warns that a loose fit, water on the wrist, or heavy sweating can affect detection. Any optical sensor has that problem, and it's worth remembering that the moment this feature matters most is the moment those conditions are most likely.
And the fundamental one: Honor says the Watch 6 Pro is not a medical device. It may miss events. It may raise false alarms. Both of those are normal for a consumer wearable making a cardiovascular judgement, but they're the two sentences that matter most in the entire announcement.
Finally, this is a China launch. There's no international release announced, and no reason to assume the cardiac functions travel with the hardware if it does.
Google Got Here First, With a Different Trade
Honor is not the first company to ship this idea. Google's Loss of Pulse Detection arrived on the Pixel Watch 3, first in Europe in 2024 and then in the US after FDA clearance in February 2025.
Google's version samples green LED PPG roughly once per second, validates against infrared and red light sensors, adds motion data, and hands the decision to an AI model. Its escalation is a check-in, then a 30-second audible alarm with a countdown, then an automated emergency call with your location over LTE.
The numbers Google published are instructive. Sensitivity in controlled arterial occlusion testing was 67.23%, meaning it missed roughly a third of the events it was shown. False positives came in at about one per 21.67 user-years. That's the real shape of this technology: it will fail to catch some collapses, and it will occasionally fire when nothing is wrong.
Honor's version goes further on the response side. Satellite fallback and asking bystanders for help are both things Google's implementation doesn't do. Whether Honor's detection is better is unknown, because Honor hasn't published comparable sensitivity or false-positive figures.
The Rest of the Health Stack Is More Complicated
Honor is calling the Watch 6 Pro's blood pressure system Blood Pressure 2.0. It uses the same optical sensing hardware to estimate readings, so there's no inflatable cuff, which is the whole difference between this and Huawei's Watch D3 approach. Honor says the software adds AI interpretation and looks at blood pressure alongside activity, sleep and emotional state. It's tied to the health research programme too, and it is not a medical blood pressure monitor.
There's also blood glucose tracking, and this one is worth reading carefully. The Watch 6 Pro displays readings from an external CGM sensor, specifically a Sinocare device. It does not measure glucose itself. That distinction has been a recurring problem in this category, and the FDA warned manufacturers about non-invasive glucose claims back in 2024.
Of the health features, ECG is the only one Honor describes as carrying medical device certification through China's NMPA. Everything cardiovascular beyond that is research-grade.
The Hardware
The display is the other unusual choice. Honor claims the Watch 6 Pro's 1.5-inch dual-layer OLED is a first for a wearable, with global excitation brightness of 4,500 nits and local peak brightness up to 5,500 nits.
Battery is rated at:
- Up to 18 days on lighter use
- Around 10 days typical
- 7 days with always-on display
- Around 4 days with full health monitoring running
Pricing starts at CNY 1,699 in China, which works out to roughly $253. Steel and nano-microcrystalline ceramic variants run higher, up to CNY 1,899, and Chinese subsidy pricing brings some configurations down to around CNY 1,444.
Bottom Line
The Watch 6 Pro is the most ambitious consumer cardiac arrest feature announced so far, and it beats Google's on the response side by adding satellite fallback and bystander alerts. It also lands behind a research programme wall, in one market, with the vendor stating plainly that it can miss the event it exists to catch.
If you're in China and you want it, the hardware is there. If you're anywhere else, the interesting part is what Honor does next, because a cardiac arrest feature shipped to one market behind a research enrolment is a test, not a product.
The sensitivity number is the one to watch for. Google published theirs. Honor hasn't.
Sources: Honor's Watch 6 Pro announcement and launch specifications for the cardiac arrest monitoring system, its four-level response, the 1.5 to 3 second assessment window, the satellite communication fallback and the AED on-screen instructions, along with Blood Pressure 2.0, the Sinocare CGM integration, the NMPA-certified ECG and the display and battery figures; Honor's stated caveats covering research programme enrolment, emergency contact and SMS configuration, Bluetooth dependency, fit and moisture effects, and its position that the device is not a medical device; Google's Loss of Pulse Detection documentation and its published 67.23 percent sensitivity figure and one false positive per 21.67 user-years; the FDA's 2024 safety communication on non-invasive blood glucose claims; and reporting from Notebookcheck on the CNY 1,699 launch price, Huawei Central on the steel and ceramic variant pricing, and GSMArena on the pre-order configurations.
